Sensors for Cancer Diagnosis

Zimmer and Peacock are attending the conference 'Sensors for Cancer Diagnosis'.  We will be sponsoring two talks:


1) Talk One - Commercializing Biosensors for Cancer Diagnostics.


2) Talk Two - Sensors for Cancer Detection.


See the buttons below for more information.

Cancer is a ubiquitous disease affecting 1 in 2 of us.


In almost 50% of cases it is diagnosed at the later stage 3 or 4, where the probability of a cure is significantly reduced.


There is an urgent worldwide need for earlier stage diagnostic tools


The application of biosensors and related technology including liquid biopsies and sequencing are beginning to emerge as possible diagnostic tools for cancer


Following Sensor100's Workshop Biosensors for Cancer Diagnosis in 2016, this Conference will bring together academic researchers, clinicians and the medical device industry to explore the current and future opportunities for the application of biosensors and other technology in the diagnosis of cancer




Issues the Conference will explore include:


Cancer biology: when does a cell become cancerous; cellular detection limits to diagnose cancer

Biomarkers for cancer: molecular, exosomes, CTCs, mDNA etc

Current state of sensor development for cancer biomarkers

Alternate technology: liquid biopsies; sequencing

Sensitivity issues: diagnosis at pre-symptomatic stage, later stage diagnosis or monitoring diagnosed disease

Companion diagnostics: do sensors have a role

Future opportunities: where is the technology heading

Barriers to adopting new diagnostic technology

Why Attend the Conference


Developing early stage, non-invasive, low cost, sensitive and accurate diagnostic tests for cancer is among the world's great technological challenges. Development of biosensors for screening for cancer, or at least its most common forms, would represent the greatest humanitarian and commercial achievement of sensor technology


The Conference will be of value to academic and commercial researchers in sensors and cancer biology, medical device companies, oncologists, pharmaceutical companies, research funding organisations